TSH Biopharm (8432) is a TW-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of NT
.9B, trading at NT$50.10 on the TWO. This SniperIQ fundamentals page covers TSH Biopharm's valuation (P/E 13.0x, P/B 1.3x), profitability (net margin 12.2%), revenue (NT
.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market CapNT
.9B
P/E (TTM)13.0x
Net Margin12.2%
Revenue (FY25)NT
.3B
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is TSH Biopharm's market cap?
TSH Biopharm (8432) has a market capitalization of approximately NT
.9B, trading at NT$50.10 on the TWO. Market cap moves with the live share price.
What is TSH Biopharm's P/E ratio?
TSH Biopharm's trailing twelve-month P/E ratio is 13.0x, with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is TSH Biopharm?
TSH Biopharm runs a net profit margin of 12.2%, a gross margin of 50.5%, and an operating margin of 17.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does TSH Biopharm generate?
TSH Biopharm reported revenue of NT
.3B for fiscal year 2025, with net income of NT
39M and earnings per share (EPS) of 3.63. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does TSH Biopharm pay a dividend?
TSH Biopharm offers a trailing dividend yield of about 5.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is TSH Biopharm financially healthy?
TSH Biopharm carries a debt-to-equity ratio of 0.02x and a current ratio of 6.44x, with a market beta of 0.32. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is TSH Biopharm a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For TSH Biopharm (8432) the key facts are: market cap NT
.9B, P/E 13.0x, revenue NT
.3B, 52-week range 45.9-59.3. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track TSH Biopharm's full fundamentals live
Get TSH Biopharm's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.